Tuesday 20 August 2024
Analog Devices and Flagship Pioneering, the bioplatform innovation company, have announced a strategic alliance to accelerate the development of a fully digitised biological world.
Breakthrough solutions
This partnership will bridge ADI’s expertise in engineering for analog and digital semiconductors with Flagship Pioneering’s expertise in applied biology to foster the discovery of biological insights, new and enhanced measurements, diagnostics, and novel interventions. The partnership represents the opportunity to create breakthrough solutions for human health and sustainability.
Specifically, the partnership will leverage Flagship Pioneering’s and create new companies in the digital biology space.Initial areas of focus will include bioelectronic platforms, regenerative agriculture, novel applications of AI/ML, and preemptive health and medicine.
Vincent Roche, CEO and chair at ADI, left, and Noubar Afeyan, PhD, founder and CEO of Flagship Pioneering, conversing during a fireside chat on stage at ADI’s general technical conference on April 25, 2024, in Boston, Massachusetts.
Potential advancements may further drive next-generation protein sequencing, multiomics, early disease diagnostics, transformation of large biological information to actionable digital data, drug design and optimisation, and more. This partnership is the latest in Flagship Pioneering’s Enabling Technologies Initiative, which is focused on the development of new therapeutic modalities by enabling and powering advanced technologies.
“At its core, ADI exists to accelerate breakthroughs that enrich lives and the world around us,” said Vincent Roche, CEO and Chair at ADI.
“Innovative technology has the potential to enable better and more proactive care. We expect our digital biology partnership with Flagship Pioneering will put the Intelligent Edge at the centre of innovating data-informed health solutions for some of today's biggest challenges.”
“Fuelled by technological leaps and deep biological understanding, we have entered a new era of biomedical and life science innovation, enabling ever-greater advances to improve the health of humans and the planet,” said Noubar Afeyan, PhD, founder and CEO of Flagship Pioneering.
'Harnesses nature’s intelligence'
“Flagship and ADI have a shared ambition and complementary strengths to accelerate the development of a fully digitised biological world that harnesses nature’s intelligence to create solutions for preventative and therapeutic medicines, regenerative agriculture, and threats from climate change.”
The partnership will be fuelled by Flagship Pioneering’s origination process for pioneering and scaling novel technologies and/or biological insights that have led to new types of therapeutic modalities such as mRNA, tRNA, and epigenetic controllers.
ADI’s current applications of sensor technologies, microfabrication technologies, and automation for healthcare including diagnostics, imaging, therapeutic devices, and continuous monitoring will underpin the combinatorial innovation driven through this engagement.
Flagship Pioneering’s scientist-entrepreneurs will partner with ADI’s scientists and engineers to conceive and create new bioplatforms that build on capabilities to bridge biology and technology, advancing novel human health and sustainability innovations.